Abstract

As companies strive to identify the most efficacious hits against a range of different targets, many companies, in addition to traditional small molecule approaches and exploring other modalities such as oligopeptides, peptides, drug conjugates, in their quest to produce the “best” drugs. This presentation explores a range of non-small molecule modalities and their role in drug discovery today.